BMY News 50.71 04/25/2014 05:11:15 Bristol-Myers Squibb Company

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bristol-Myers Squibb Company (BMY) 50.71 $BMY

What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...

Final Glance: Pharmaceuticals companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Alexion Posts Strong Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:00PM CDT
Alexion (ALXN) handsomely beat the Zacks Consensus Estimate in the first quarter.

Midday Glance: Pharmaceuticals companies
AP - Thu Apr 24, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List
Business Wire - Thu Apr 24, 12:01PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders.

The Medicines Co.'s Q1 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 10:40AM CDT
The Medicines Co. (MDCO) also announced an acquisition agreement which reflects its efforts to diversify its portfolio and reduce its dependence on Angiomax.

Early Glance: Pharmaceuticals companies
AP - Thu Apr 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Is This Struggling Drugmaker Worth $100 Billion?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
The pharmaceutical world got a shock this week from   reports that  Pfizer    had engaged in informal talks with Big Pharma rival  AstraZeneca    about a possible $100 billion acquisition. AstraZeneca reportedly  expressed no interest in the...

The Zacks Analyst Blog Highlights andora Media, Apple, Sirius XM, Bristol-Myers Squibb and Five Prime Therapeutics
PR Newswire - Thu Apr 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Pandora Media, Inc. (NYSE -Free Report), Apple (Nasdaq:AAPL-Free Report), Sirius XM (Nasdaq:SIRI-Free Report), Bristol-Myers Squibb Company (NYSE:BMY-Free Report) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX-Free Report).

AstraZeneca's Q1 Profit Falls 11% Despite Strong Diabetes Drug Growth
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 24, 7:36AM CDT
Just days after rumors swirled about a possible takeover offer, global pharmaceutical giant AstraZeneca reported its first-quarter results very early this morning, delivering modest top-line growth but seeing its profits shrink notably. For...

Allied Minds Names Peter Dolan and Jeff Rohr to Board of Directors
Business Wire - Thu Apr 24, 7:03AM CDT
Allied Minds, a dedicated technology commercialization firm that develops businesses and products based on innovative technologies developed at US universities and federal research institutions, today announced the appointment of Peter Dolan and Jeff Rohr as new members of its Board of Directors, effectively immediately.

Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.

Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...

Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.

AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.

Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...

Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading